06:34 EDT Regeneron lowers FY24 CapEx view to $780M-$880M from $825M-$950M
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces presentations on EYLEA HD, EYLEA Injection at ARVO meeting
- EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
- Regeneron price target raised to $1,175 from $1,125 at Oppenheimer
- Regeneron, Mammoth collaborate to purse next-generation gene editing
- Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO